Clinical trials
Resistance clinical trials
Below are recruiting resistance clinical trials, each written for real people, not researchers. We’re tracking 1,198 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05820893RecruitingPhase 2
Resistant potato starch for Gulf War gut and fatigue
This Phase 2 study tests whether resistant potato starch can improve Gulf War illness (GWI), especially gut symptoms and fatigue, in older adults. You may be asked to follow a study plan and provide stool samples, while avoiding certain medications and recent infections.
Madison, WisconsinAges 50–85 - NCT05835206RecruitingPhase 2
Drug to reduce antibiotic-resistant gut bacteria
This Phase 2 study tests whether an investigational treatment can help clear or reduce antibiotic-resistant bacteria living in the gut. It may help prevent these germs from causing future infections by targeting specific resistant bacteria found on stool or rectal swabs.
Atlanta, GeorgiaAges 18 years+ - NCT05805371RecruitingPhase 1
PSCA CAR-T cells with or without radiation for prostate cancer
This Phase 1 study tests a prostate cancer treatment made of PSCA-targeted CAR-T cells, with or without radiation, to help control advanced prostate cancer. It aims to find a safe treatment approach and see how well it works in people whose cancer has PSCA.
Duarte, CaliforniaAges 18 years+ - NCT05756322RecruitingPhase 1/Phase 2
Study medicine LBS-007 for relapsed leukemia patients
This trial tests how safe and tolerable LBS-007 is for adults with AML or ALL that has come back or is resistant to treatment. It may help people who can’t use standard therapies or have no proven treatment options.
Tampa, FloridaAges 18–120 - NCT05734391Enrolling by invitation
Tracking hospital infections and germs from nose and rectum swabs
This trial monitors healthcare-associated infections and antibiotic resistance by collecting swabs from the nose and rectum while you are hospitalized. It may help doctors better understand how often these infections happen and how to prevent them.
Philadelphia, PennsylvaniaAges Any age - NCT05743868Recruiting
Study of how insulin resistance affects blood fats
This study looks at how differences in insulin resistance may change how the liver makes triglycerides (a type of blood fat). It may help researchers understand why some people have higher triglycerides and how to target them better.
AmsterdamAges 18–65 - NCT05660642RecruitingPhase 2
Safety and tolerability study for BPL-003 in hard-to-treat depression
This Phase 2 study tests BPL-003 in people with treatment-resistant depression to learn about its safety and how it affects the body and brain. Because it is open-label, everyone knows they are getting the study treatment, and you’ll also need to stop your current antidepressant during the study.
LiverpoolAges 18–75 - NCT05613894RecruitingPhase 1
Combination treatment for advanced prostate cancer
This study tests a combination of two drugs for men with advanced prostate cancer that has stopped responding to hormone therapy. The drugs are cabozantinib (a pill that may slow cancer growth) and a radioactive therapy that targets prostate cancer cells (177Lu-PSMA-617). The goal is to see if this combination is safe and effective.
Salt Lake City, UtahAges 18 years+ - NCT05570344Recruiting
Texting support plus brain stimulation for hard-to-treat depression
This study tests whether adding supportive text messages to brain stimulation (repetitive TMS) helps people with depression that has not improved after at least two antidepressant tries. It may help some people by combining a brain-based treatment with ongoing daily encouragement and support.
Edmonton, AlbertaAges 18 years+ - NCT05577247Recruiting
Study of new thinking skills in hard-to-treat depression
This trial looks at how people with treatment-resistant major depression respond when starting a new depression medicine that affects glutamate signaling. It also involves brain scans and thinking/learning tasks, aiming to understand what helps people improve when standard treatments haven’t worked.
ParisAges 18–70 - NCT05570994Enrolling by invitationPhase 1/Phase 2
PSMA-targeted radioactive drug for advanced prostate cancer
This Phase 1/2 study tests a radioactive treatment that targets PSMA, a protein often found on prostate cancer cells. It’s for men whose prostate cancer has worsened despite hormone-blocking pills like abiraterone or enzalutamide, aiming to help shrink or control the disease.
Vancouver, British ColumbiaAges 18 years+ - NCT05553236Recruiting
Using gene testing to guide treatment for drug-resistant tuberculosis
This study uses next-generation gene testing to help manage active drug-resistant tuberculosis. It may help doctors choose the most appropriate treatment by better identifying the TB’s drug resistance.
Cape TownAges Any age - NCT05534646RecruitingPhase 2
Carotuximab plus hormone therapy for advanced prostate cancer
This trial tests a new drug called carotuximab given with a standard hormone therapy (apalutamide or enzalutamide) for men with prostate cancer that has stopped responding to current hormone treatments. The goal is to see if this combination can slow the cancer's growth and lower PSA levels.
Duarte, CaliforniaAges 18 years+ - NCT05521412RecruitingPhase 1/Phase 2
PSMA-targeted radioligand for advanced prostate cancer
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
Melbourne, VictoriaAges 18 years+ - NCT05348876RecruitingPhase 4
Darolutamide plus standard hormone therapy for high-risk prostate cancer
This trial studies how safe darolutamide is and how well it works when added to standard hormone therapy for men with high-risk, non-metastatic prostate cancer that is no longer responding to hormone treatment. It may help slow prostate cancer growth and reduce prostate-specific antigen (PSA) rises in real-world care.
Vijayawada, Andhra PradeshAges 18 years+ - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Mobile, AlabamaAges 18 years+ - NCT05225363RecruitingPhase 1
CAR T therapy for ovarian cancer that no longer responds to platinum
This Phase 1 study tests a one-time treatment made from your immune cells (CAR T) to attack a protein found on some ovarian cancer cells. It is for people whose ovarian cancer has come back or worsened after platinum chemotherapy, aiming to see safety and early signs of benefit.
Duarte, CaliforniaAges 18 years+ - NCT05188027Recruiting
Exercise types for postmenopausal women with type 1 diabetes
This study compares aerobic exercise (like brisk walking) versus resistance exercise (like strength training) to see which works better for women with type 1 diabetes after menopause. It may help you learn which exercise approach is safest and most helpful for blood sugar and health.
Edmonton, AlbertaAges 45–75 - NCT05173714RecruitingPhase 2
Sit Less and Move More program for people with CKD
This Phase 2 study tests a program to help people with chronic kidney disease (CKD) sit less and move more, plus a medication (semaglutide) for those who qualify. It may help improve health and day-to-day activity while monitoring safety closely.
Stanford, CaliforniaAges 20 years+ - NCT05163600Recruiting
Exercise with or without blood flow restriction for health
This study compares how your heart and lungs respond to two different types of exercise: one with a special cuff that slightly limits blood flow and one without. It may help if you are healthy or have COPD.
Zurich, Canton of ZurichAges 18–90 - NCT05116137Enrolling by invitation
Exercise therapy to build muscle after glioblastoma
This trial studies whether a resistance (strength-building) exercise program can help survivors of glioblastoma keep or increase their muscle mass. If you are able to safely exercise, it may support recovery and overall strength after treatment.
Halifax, Nova ScotiaAges 18 years+ - NCT04986423RecruitingPhase 2
Add ZEN003694 to enzalutamide for resistant prostate cancer
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
Los Angeles, CaliforniaAges 18 years+ - NCT04996433Recruiting
Compare two talk therapy programs for treatment-resistant depression
This study compares two psychotherapy programs to help people who have ongoing, difficult-to-treat depression while in inpatient care. If you qualify, you’ll receive one of the therapy programs and be followed to see which approach helps depression symptoms more.
Berlin, State of BerlinAges 18–75 - NCT04868604RecruitingPhase 1/Phase 2
Copper PSMA scan and treatment for prostate cancer in men on low testosterone
This trial tests a PSMA-targeted copper medicine used after a special PSMA PET/CT scan to find and treat prostate cancer that has spread. It’s for men whose testosterone is already very low and whose cancer is growing despite hormone-blocking medicines like enzalutamide or abiraterone.
Stanford, CaliforniaAges 18 years+
Hear when a new Resistance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resistance?
- Yes. Clin2 currently lists 1,198 recruiting resistance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resistance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resistance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.